Transdermal Oxybutynin: What Role in the Management of Overactive Bladder?

Clinical Medicine Insights: Therapeutics - New Zealand
doi 10.4137/cmt.s2608
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain

Journal of Health Economics and Outcomes Research
2018English

Oxybutynin Extended Release for the Management of Overactive Bladder: A Clinical Review

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2009English

Development of Oxybutynin Chloride Topical Gel for Overactive Bladder

Research and Reports in Urology
Urology
2011English

Management of Overactive Bladder

2018English

PUK10 Cost-Effectiveness Analysis of Solifenacin Versus Oxybutynin Immediate-Release in the Treatment of Patients With Overactive Bladder in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Overactive Bladder in the Vulnerable Elderly

Research and Reports in Urology
Urology
2014English

New Developments in the Management of Overactive Bladder: Focus on Mirabegron and onabotulinumtoxinA

Therapeutics and Clinical Risk Management
2013English

The Second-Line Management of Idiopathic Overactive Bladder: What Is the Place of Sacral Neuromodulation and Botulinum Toxin-A in Contemporary Practice?

BJU International
Urology
2009English

OnabotulinumtoxinA for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy